Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
3 Under-the-Radar Biotech Stocks to Buy in 2023
07:40am, Saturday, 19'th Aug 2023
Deciphera Pharmaceuticals' lead therapy is Qinlock, to treat gastrointestinal stromal tumors. Mirati Therapeutics' Krazati is showing promise as a part of a combination therapy.
Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
11:27am, Wednesday, 09'th Aug 2023
Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down.
Why Shares of Mirati Therapeutics Are Jumping Wednesday
10:56am, Wednesday, 09'th Aug 2023
With the stock rising, the company also announced a $300 million public stock offering. Krazati is Mirati's lead therapy for treating non-small cell lung cancer (NSCLC) that has spread to other parts
Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Call Transcript
08:51pm, Tuesday, 08'th Aug 2023
Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Ryan Asay - Vice President-Corporate Affairs Chuck Baum - President, Founder &
Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates
07:41pm, Tuesday, 08'th Aug 2023
Mirati (MRTX) came out with a quarterly loss of $3.04 per share versus the Zacks Consensus Estimate of a loss of $3.23. This compares to loss of $3.18 per share a year ago.
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
04:30pm, Tuesday, 25'th Jul 2023
SAN DIEGO , July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with rec
Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing
01:05pm, Monday, 24'th Jul 2023
Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.
Mirati Therapeutics shares fall after lung cancer drug gets negative opinion from European regulators
08:06am, Friday, 21'st Jul 2023
Shares of Mirati Therapeutics Inc. MRTX, -2.40% were down 4.7% premarket on Friday after the company said the European Medicines Agency had issued a negative opinion on a marketing application for Kra
EU regulator declines to back Mirati's lung cancer drug
06:22am, Friday, 21'st Jul 2023
Mirati Therapeutics said on Friday the European regulator's panel for medical products has declined to recommend an authorization for the company's drug to treat of a type of lung cancer.
Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%
03:47pm, Thursday, 25'th May 2023
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
12:55pm, Wednesday, 10'th May 2023
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday.
Mirati Therapeutics, Inc. (MRTX) Q1 2023 Earnings Call Transcript
10:44pm, Tuesday, 09'th May 2023
Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Ryan Asay – Vice President-Corporate Affairs David Meek – Chief Executive Offi
Mirati (MRTX) Reports Q1 Loss, Tops Revenue Estimates
07:07pm, Tuesday, 09'th May 2023
Mirati (MRTX) came out with a quarterly loss of $3.18 per share versus the Zacks Consensus Estimate of a loss of $3.47. This compares to loss of $3.40 per share a year ago.
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
04:30pm, Tuesday, 25'th Apr 2023
SAN DIEGO , April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with rec
Mirati's Krazati: A Strong Competitor In The KRAS G12C-Mutated NSCLC Market
03:43am, Monday, 20'th Mar 2023
Mirati Therapeutics specializes in developing cancer treatments targeting genetic and immunological causes, with Krazati being their first FDA-approved product. Krazati is used to treat adult patients
